Format
Sort by
Items per page

Send to

Choose Destination

Best matches for ATAZANAVIR/AE:

Atazanavir: urolithiasis. et al. Prescrire Int. (2014)

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. Martinez E et al. HIV Med. (2014)

Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection. Nishijima T et al. J Antimicrob Chemother. (2014)

Search results

Items: 1 to 20 of 42

1.

Naringin prevents HIV-1 protease inhibitors-induced metabolic complications in vivo.

Nzuza S, Zondi S, Owira PMO.

PLoS One. 2017 Nov 9;12(11):e0183355. doi: 10.1371/journal.pone.0183355. eCollection 2017.

2.

Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?

Metsu D, Toutain PL, Chatelut E, Delobel P, Gandia P.

J Antimicrob Chemother. 2017 Sep 1;72(9):2407-2409. doi: 10.1093/jac/dkx176.

PMID:
28595364
3.

Atazanavir-Associated Crystalline Nephropathy.

Santoriello D, Al-Nabulsi M, Reddy A, Salamera J, D'Agati VD, Markowitz GS.

Am J Kidney Dis. 2017 Oct;70(4):576-580. doi: 10.1053/j.ajkd.2017.02.376. Epub 2017 Jun 2.

PMID:
28579422
4.

Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).

Hwang C, Schürmann D, Sobotha C, Boffito M, Sevinsky H, Ray N, Ravindran P, Xiao H, Keicher C, Hüser A, Krystal M, Dicker IB, Grasela D, Lataillade M.

Clin Infect Dis. 2017 Aug 1;65(3):442-452. doi: 10.1093/cid/cix239.

5.

Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.

Menshawy A, Ismail A, Abushouk AI, Ahmed H, Menshawy E, Elmaraezy A, Gadelkarim M, Abdel-Maboud M, Attia A, Negida A.

Arch Virol. 2017 Aug;162(8):2181-2190. doi: 10.1007/s00705-017-3346-9. Epub 2017 Mar 30. Review.

PMID:
28361290
6.

Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.

Postorino MC, Prosperi M, Focà E, Quiros-Roldan E, Di Filippo E, Maggiolo F, Borghetti A, Ladisa N, Di Pietro M, Gori A, Sighinolfi L, Pan A, Mazzini N, Torti C.

BMC Infect Dis. 2017 Mar 15;17(1):212. doi: 10.1186/s12879-017-2322-z.

7.

Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.

Jose S, Nelson M, Phillips A, Chadwick D, Trevelion R, Jones R, Williams DI, Hamzah L, Sabin CA, Post FA; UK CHIC study.

AIDS. 2017 Feb 20;31(4):485-492. doi: 10.1097/QAD.0000000000001353.

8.

Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.

Harris M, Ganase B, Watson B, Hull MW, Guillemi SA, Zhang W, Saeedi R, Harrigan PR.

HIV Clin Trials. 2017 Jan;18(1):39-47. doi: 10.1080/15284336.2016.1271503. Epub 2017 Jan 9.

PMID:
28067119
9.

Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.

Marinaro L, Calcagno A, Ripamonti D, Cenderello G, Pirriatore V, Trentini L, Salassa B, Bramato C, Orofino G, D'Avolio A, Rizzi M, Di Perri G, Rusconi S, Bonora S.

J Clin Virol. 2017 Feb;87:30-36. doi: 10.1016/j.jcv.2016.11.015. Epub 2016 Dec 1.

PMID:
27992788
10.

Managing chronic kidney disease in the older adults living with HIV.

Post FA.

Curr Opin Infect Dis. 2017 Feb;30(1):4-11. doi: 10.1097/QCO.0000000000000333. Review.

PMID:
27828808
11.

Acute intermittent porphyria precipitated by atazanavir/ritonavir.

Bharti S, Malhotra P, Hirsch B.

Int J STD AIDS. 2016 Nov;27(13):1234-1235. Epub 2016 Feb 11.

PMID:
26872826
12.

Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?

Metsu D, Seraissol P, Delobel P, Cinq-Frais C, Cuzin L, Izopet J, Chatelut E, Gandia P.

Fundam Clin Pharmacol. 2017 Apr;31(2):245-253. doi: 10.1111/fcp.12245. Epub 2016 Oct 25.

PMID:
27664801
13.

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.

Gallant J, Moyle G, Berenguer J, Shalit P, Cao H, Liu YP, Myers J, Rosenblatt L, Yang L, Szwarcberg J.

Curr HIV Res. 2017;15(3):216-224. doi: 10.2174/1570162X14666161021102728.

14.

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study.

Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura V, Falconer K, Maltez F, Beniowski M, Vullo V, Hassoun G, Kuzovatova E, Szlavik J, Kuznetsova A, Stellbrink HJ, Duvivier C, Edwards S, Laut K, Paredes R; EuroSIDA Study.

Medicine (Baltimore). 2016 Oct;95(40):e5020.

15.

Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients.

Subashini D, Dinesha TR, Boobalan J, Samuel LC, Poongulali S, Pradeep A, Solomon SS, Solomon S, Balakrishnan P, Saravanan S.

Indian J Pharmacol. 2016 Sep-Oct;48(5):582-585.

16.

Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study.

Rosenblatt L, Farr AM, Nkhoma ET, Nelson JK, Ritchings C, Johnston SS.

BMC Infect Dis. 2016 Sep 19;16:492. doi: 10.1186/s12879-016-1827-1. Erratum in: BMC Infect Dis. 2016 Oct 7;16(1):547.

17.

Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.

Guillemi SA, Ling SH, Dahlby JS, Yip B, Zhang W, Hull MW, Lima VD, Hogg RS, Werb R, Montaner JS, Harris M.

J Int AIDS Soc. 2016 Sep 9;19(1):20995. doi: 10.7448/IAS.19.1.20995. eCollection 2016.

18.

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.

Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, Avihingsanon A, Koenig E, Jiang S, White K, Cheng A, Szwarcberg J, Cao H.

Lancet HIV. 2016 Sep;3(9):e410-e420. doi: 10.1016/S2352-3018(16)30016-9. Epub 2016 May 27.

19.

Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.

Bonjoch A, Puig J, Pérez-Alvarez N, Juega J, Echeverría P, Clotet B, Romero R, Bonet J, Negredo E.

Medicine (Baltimore). 2016 Aug;95(32):e4507. doi: 10.1097/MD.0000000000004507.

20.

Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.

Bunupuradah T, Kiertiburanakul S, Avihingsanon A, Chetchotisakd P, Techapornroong M, Leerattanapetch N, Kantipong P, Bowonwatanuwong C, Banchongkit S, Klinbuayaem V, Mekviwattanawong S, Nimitvilai S, Jirajariyavej S, Prasithsirikul W, Munsakul W, Bhakeecheep S, Chaivooth S, Phanuphak P, Cooper DA, Apornpong T, Kerr SJ, Emery S, Ruxrungtham K; LASA Study Group.

Lancet HIV. 2016 Aug;3(8):e343-e350. doi: 10.1016/S2352-3018(16)30010-8. Epub 2016 May 24.

PMID:
27470026

Supplemental Content

Loading ...
Support Center